National Wilm's Tumor Study Late Effects

This study has been withdrawn prior to enrollment.
(national study, local site not responsible for results/analysis)
Sponsor:
Information provided by (Responsible Party):
Howard Katzenstein, Emory University
ClinicalTrials.gov Identifier:
NCT00228696
First received: September 27, 2005
Last updated: November 23, 2013
Last verified: November 2013

September 27, 2005
November 23, 2013
September 2005
December 2010   (final data collection date for primary outcome measure)
To determine if survivors from Wilms tumors or their offspring are at risk for adverse medical conditions. [ Time Frame: 1 year after closure of study ] [ Designated as safety issue: No ]
  • To determine if participant's offsprings are at risk for adverse medical conditions.
  • To answer questions about long-term effects of treatment for Wilm's tumors.
Complete list of historical versions of study NCT00228696 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
National Wilm's Tumor Study Late Effects
National Wilm's Tumor Study Late Effects

The Late Effects Study is being conducted in order to answer scientific questions and to serve as a resource for Wilms tumor patients and their families. Patients must have been enrolled on the NWTS-5 protocol in order to be eligible for this study.

The Late Effects Study is being conducted in order to answer scientific questions and to serve as a resource for Wilms tumor patients and their families. Although most people in this study enjoy good health, some may be at risk for certain health conditions. We are collecting information from as many participants as possible in order to determine if they or their offspring are at risk for adverse medical conditions. If there is more than one case of Wilms tumor in a given family, we plan to work with geneticists to try to estimate heritability and recurrence risks.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Wilm's Tumor
Other: none, screening only
Screening protocol with no intervention
No Intervention: screening
this is a screening study and no intervention.
Intervention: Other: none, screening only
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
December 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

Previously enrolled in NWTS 5.

Both
18 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00228696
IRB00024842
Yes
Howard Katzenstein, Emory University
Emory University
Not Provided
Principal Investigator: Howard Katzenstein, MD Children's Healthcare of Atlanta
Emory University
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP